A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: LT3001 Drug ProductDrug: Placebo
- Registration Number
- NCT04091945
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Brief Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 24
- 18 to 90 years
- NIHSS of 4 to 30
- Diagnosis of AIS within 24 hours after stroke symptoms onset
- Treatement with approved drug during the current AIS
- Pre-stroke disability
- Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor, arteriovenous malformations, other central nervous system lesions that could increase bleeding risk, or aneurysm requiring treatment
- Suspected subarachnoid hemorrhage
- Seizure
- Uncontrolled hypertension
- INR >1.7 and/or abnormal aPTT or platelet count <100,000/mm3
- Blood glucose concentration <50 mg/dL or >400 mg/dL
- Lactating or pregnant subjects or those planning to become pregnant during the study
- Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa inhibitors within 48 hours
- AIS, myocardial infarction, serious head trauma or major surgery within 90 days
- Bleeding event within 21 days
- Puncture of noncompressible vessels within 7 days
- Severe hepatic, renal, and/or infectious disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LT3001 Drug Product LT3001 Drug Product - Placebo Placebo -
- Primary Outcome Measures
Name Time Method The percentage of subject have symptomatic intracranial hemorrhage (sICH) of a single dose LT3001 drug product in subjects with AIS. Within 36 hours Compare the the percentage of subject having symptomatic intracranial hemorrhage (sICH) between LT3001 drug product and Placebo.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
China Medical University Hospital
π¨π³Taichung, Taiwan
Chattanooga Center for Neurologic Research
πΊπΈChattanooga, Tennessee, United States
JFK Neuroscience Institute, JFK Medical Center
πΊπΈEdison, New Jersey, United States
University of Kentucky Chandler Medical Center
πΊπΈLexington, Kentucky, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital
π¨π³Kaohsiung, Taiwan
Linkou Chang Gung Memorial Hospital
π¨π³New Taipei City, Taiwan
Taichung Veterans General Hospital
π¨π³Taichung, Taiwan
Taipei Medical University - Shuang Ho Hospital
π¨π³New Taipei City, Taiwan
Taipei Veterans General Hospital
π¨π³Taipei, Taiwan
The Ohio State University - Wexner Medical Center
πΊπΈColumbus, Ohio, United States